The first major improvements in B-cell non-Hodgkin lymphoma survival rates since the 1970s occurred following the introduction of rituximab, Australian research shows. A study of outcomes for lymphoma in Queensland patients over the last two decades found there were increases in overall survival rates of around 13% for the two most common subtypes, diffuse large ...
Lymphoma survival rates improved in rituximab era
By Michael Woodhead
15 Aug 2018